甲磺酸二氢麦角胺 | 6190-39-2

• 物质功能分类: 原料药 - 循环系统用药 - 周围血管扩张药
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 中文名称: 甲磺酸二氢麦角胺
• 中文别名: 双氢麦角胺甲磺酸盐；甲磺双氢麦角胺
• 英文名称: dihydroergotamine mesylate
• 英文别名: dihydroergotamine methane sulfonate salt；dihydroergotamine methanesulfonate；(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-7-ium-9-carboxamide;methanesulfonate
• CAS: 6190-39-2
• 化学式: CH₄O₃S*C₃₃H₃₇N₅O₅
• 分子量: 679.794
• InChiKey: ADYPXRFPBQGGAH-UMYZUSPBSA-N

物化性质

• 熔点：
  232°C
• 溶解度：
  在甲醇中可溶21 mg/mL
• 碰撞截面：
  227.4 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  48
• 可旋转键数：
  4
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  181
• 氢给体数：
  4
• 氢受体数：
  9

ADMET

毒理性

• 在妊娠和哺乳期间的影响

使用期间对哺乳的影响：目前没有关于哺乳期间使用双氢麦角胺的临床信息。由于它可能会对婴儿产生不良影响并减少乳汁供应，大多数权威机构认为在哺乳期间禁用麦角胺。双氢麦角胺鼻喷剂的制造商建议，在接受治疗的哺乳期母亲不应哺乳，并在最后一次给药后3天内停止哺乳。在此期间泵出的任何乳汁都应丢弃。 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the clinical use of dihydroergotamine during breastfeeding. Because it might cause adverse effects in the infant and decrease the milk supply, most authorities consider ergotamine to be contraindicated during nursing. The manufacturer of the dihydroergotamine nasal spray recommends that nursing mother should not breastfeed during treatment and for 3 days after the last dose. Any milk that is pumped during this time should be discarded. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

安全信息

• 危险等级：
  6.1(b)
• 危险品标志：
  Xn
• 安全说明：
  S36
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2939690000
• RTECS号：
  KE7920000
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 危险品运输编号：
  1544
• 储存条件：
  存储于室温下

SDS

Dihydroergotamine Mesylate Revision number: 5
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: Dihydroergotamine Mesylate

Revision number: 5

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS
Acute toxicity (Oral) Category 4
Category 4
Acute toxicity (Dermal)
Acute toxicity (Inhalation) Category 4
Not classified
ENVIRONMENTAL HAZARDS
GHS label elements, including precautionary statements
Pictograms or hazard symbols
Signal word Warning
Hazard statements Harmful if swallowed, in contact with skin or if inhaled
Precautionary statements:
Avoid breathing dust/fume/gas/mist/vapours/spray.
[Prevention]
Use only outdoors or in a well-ventilated area.
Do not eat, drink or smoke when using this product.
Wash hands thoroughly after handling.
Wear protective gloves and eye/face protection.
[Response] IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for
breathing. Call a POISON CENTER or doctor/physician if you feel unwell.
IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
Rinse mouth.
IF ON SKIN: Gently wash with plenty of soap and water.
Wash contaminated clothing before reuse.
Call a POISON CENTER or doctor/physician if you feel unwell.
[Disposal] Dispose of contents/container through a waste management company authorized by
the local government.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Components: Dihydroergotamine Mesylate
Percent: ....
6190-39-2
CAS Number:
Synonyms: Dihydroergotamine Methanesulfonate
Dihydroergotamine Mesylate

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Chemical Formula: C33H37N5O5·CH4O3S

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Call a POISON CENTER or doctor/physician if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Call a POISON CENTER or doctor/physician if you feel unwell. Rinse mouth.
Ingestion:
Protection of first-aiders: A rescuer should wear personal protective equipment, such as rubber gloves and air-
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Dry chemical, foam, water spray, carbon dioxide.
Suitable extinguishing
media:
Specific hazards arising Take care as it may decompose upon combustion or in high temperatures to
from the chemical: generate poisonous fume.
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store away from incompatible materials such as oxidizing agents.
Light-sensitive
Packaging material: Comply with laws.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Install a closed system or local exhaust as possible so that workers should not be
Engineering controls:
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.
Dihydroergotamine Mesylate

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Crystal- Powder
Form:
Colour: Very pale red - Pale red
No data available
Odour:
pH: No data available
Melting point/freezing point:No data available
Boiling point/range: No data available
No data available
Flash point:
Flammability or explosive
limits:
Lower: No data available
No data available
Upper:
Relative density: No data available
Solubility(ies):
[Water] No data available
No data available
[Other solvents]

---

Section 10. STABILITY AND REACTIVITY
Chemical stability: Stable under proper conditions.
Possibility of hazardous No special reactivity has been reported.
reactions:
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx), Sulfur oxides
products:

---

Section 11. TOXICOLOGICAL INFORMATION
orl-rat LD50:>2000 mg/kg
Acute Toxicity:
Skin corrosion/irritation: No data available
No data available
Serious eye
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
No data available
IARC =
NTP = No data available
No data available
Reproductive toxicity:
RTECS Number: KE7920000

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobility in soil
Log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.
Dihydroergotamine Mesylate

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not listed

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性方面，Dihydroergotamine甲磺酸盐是一种麦角生物碱，能够用于治疗偏头痛。

反应信息

• 作为反应物：
  描述：

  甲磺酸二氢麦角胺 在 水 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 123.0h， 生成 9,10-二氢麦角酸
  参考文献：
  名称：

  [EN] ERGOLINE DERIVATIVES AS DOPAMINE RECEPTOR MODULATORS
  [FR] DÉRIVÉS D'ERGOLINE EN TANT QUE MODULATEURS D'UN RÉCEPTEUR DE LA DOPAMINE

  摘要：

  该发明提供了式(I)的化合物，其中R1-R4具有规范中定义的任何值，以及其盐。这些化合物可用作多巴胺受体调节剂，用于治疗多巴胺受体调节受牵扯的疾病（例如性功能障碍、垂体催乳素瘤、帕金森病和库欣氏症）。

  公开号：

  WO2014078857A1

文献信息

• Alpha2C adrenoreceptor agonists
  申请人：McCormick D. Kevin

  公开号：US20070093477A1

  公开（公告）日：2007-04-26

  In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

  在其多种实施形式中，本发明涉及一类新型的苯基吗啡啶和苯基硫代吗啡啶化合物，这些化合物可用作α2C肾上腺素受体激动剂，包含这些化合物的药物组合物，以及使用这些化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体激动剂相关的一种或多种疾病的方法。
• [EN] BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE BIARYL-SPIROAMINOOXAZOLINE EN TANT QUE MODULATEURS DE RÉCEPTEUR ADRÉNERGIQUE ALPHA2C
  申请人：SCHERING CORP

  公开号：WO2010042473A1

  公开（公告）日：2010-04-15

  In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的双芳基螺氨氧杂萘类衍生物，作为α2C肾上腺素受体激动剂的调节剂，提供了制备这类化合物的方法，包含一个或多个这类化合物的药物组合物，制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一个或多个条件的方法。
• [EN] REVERSED BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE BIARYLE SPIROAMINOOXAZOLINE INVERSÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR ALPHA2C ADRÉNERGIQUE
  申请人：SCHERING CORP

  公开号：WO2011041181A1

  公开（公告）日：2011-04-07

  In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的联苯螺环氨氧唑啉类似物，作为α2C肾上腺素受体激动剂的调节剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一种或多种疾病的方法。
• [EN] 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES 3,3-DIFLUOROPIPÉRIDINE CARBAMATE UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS NMDA NR2B
  申请人：RUGEN HOLDINGS (CAYMAN) LTD

  公开号：WO2016196513A1

  公开（公告）日：2016-12-08

  Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

  本文披露了化学实体的化学式（I），其中R1和Z如本文所定义，作为NR2B亚型选择性受体拮抗剂。还披露了包括化学实体的化学式（I）的药物组合物，以及通过给予化学实体的化学式（I）来治疗与NR2B拮抗作用相关的各种疾病和疾病的方法，例如中枢神经系统疾病和疾病，如抑郁症。
• [EN] SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE SPIROAMINOOXAZOLINE EN TANT QUE MODULATEURS DE RÉCEPTEUR ADRÉNERGIQUE ALPHA2C
  申请人：SCHERING CORP

  公开号：WO2010042475A1

  公开（公告）日：2010-04-15

  In its many embodiments, the present invention provides a novel class of spiroaminooxazoline analogues as modulators of α2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的螺环氨氧唑啉类似物，作为α2C肾上腺素受体的调节剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及利用这类化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一种或多种疾病的方法。